Xcout Intel
Aclipse Therapeutics LLC
Aclipse Therapeutics is a clinical-stage biopharmaceutical company that develops novel, disease-modifying drug candidates for severe and life-threatening conditions such as gastroparesis and amyotrophic lateral sclerosis (ALS). The company leverages genomic, proteomic, and biomarker data to target molecular pathways involving inflammation, cellular stress, and protein misfolding, while also implementing patient stratification approaches to improve clinical outcomes.
Subscribe to see Aclipse Therapeutics LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Aclipse Therapeutics LLC at a glance
Aclipse Therapeutics LLC is a biotechnology company headquartered in United States. It has raised at least $2.5M across the 5 funding rounds on record. Its most recent funding round raised $115,000 in August 2020. Xcout tracks 6 named people at Aclipse Therapeutics LLC, including Raymond K. Houck (CEO & President).
Aclipse Therapeutics LLC leadership
- Raymond K. HouckCEO & President
- Ira KalfusChief Medical Officer
- Michael KrandaChief Business Officer
- Ning ShanChief Scientific Officer
- Brian MoyerVice President, Corporate Development and Finance
- H. Joseph ReiserChairman of the Board
Aclipse Therapeutics LLC funding rounds
At least $2.5M raised across the 5 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $115,000 | — | |
| SEC Form D filing | $25,000 | — | |
| SEC Form D filing | $200,000 | — | |
| SEC Form D filing | $1.1M | — | |
| SEC Form D filing | $1.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Aclipse Therapeutics LLC competitors
A few of Aclipse Therapeutics LLC's closest competitors — see the full list of competitors and alternatives →
ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.
Libra Therapeutics is a biopharmaceutical company headquartered in Del Mar, California, focused on developing novel disease-modifying therapeutics. The company aims to restore cellular balance and improve lysosomal function to halt neurodegeneration in conditions such as amyotrophic lateral sclerosis.
Vogenx, Inc. is a clinical-stage biopharmaceutical and life science company that discovers and develops novel therapeutics to treat metabolic and gastrointestinal diseases, including post-bariatric hypoglycemia and gastroparesis. Its lead drug candidate, mizagliflozin, is an oral small molecule designed to inhibit SGLT1, reducing glucose absorption and the secretion of insulin and gastric inhibitory peptide.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
BioEclipse Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in California. The company is focused on researching and developing a novel generation of targeted immunotherapies and treatments for oncology.
Crucible Therapeutics is a biopharmaceutical company founded in 2023 to develop novel therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, originating from research at the Sheffield Institute for Translational Neuroscience.
Get Aclipse Therapeutics LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Aclipse Therapeutics LLC in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access